MedGenome is a genomics and clinical data driven diagnostics and drug discovery research company founded in 2013.
MedGenome is the market leader in genetic diagnostics in India and one of the highest throughput NGS sequencing lab in South Asia. We possess state-of-the-art Next Generation Sequencing (NGS) facility housing cutting-edge genome sequencing platforms such as Illumina’s NovaSeq, HiSeq X , HiSeq 4000 and 2500, MiSeq, etc.
Our Sequencing facility is supported by a sophisticated IHC pathology lab and we even utilize modern molecular techniques such as FISH, PCR, Sanger Sequencing and Microarray to offer comprehensive diagnostic solutions to researchers, doctors and hospitals. We currently offer more than 475 genetic tests across several disease categories such as paediatrics, neurology, oncology, hematology, endocrinology, nephrology, ophthalmology, etc.
Our footprint covers the whole of India and parts of South Asia with over 550 hospitals and more than 5,500 clinicians leveraging our services. MedGenome has successfully partnered with major hospitals and research centres across India. We have setup Genome Centres in key cities across India to create awareness about the utility and efficacy of genetic testing in a clinic and offer services that are relevant and affordable to patients to manage their health outcomes.
Innovation is a core belief and many of our tests have been developed in-house including our comprehensive Gene Panels. Our liquid biopsy test OncoTrack for monitoring cancer treatment is the only NGS-based ctDNA test available in India. We even offer carrier screening test for couples planning a baby and whole exome sequencing test for identifying gene mutations in rare diseases. We believe in continuous innovation to help reduce the cost of genetic tests and empower clinicians with actionable clinical insights to provide better outcomes.
As a firm believer in quality, MedGenome adheres to the highest international standards when it comes to our services and have obtained the prestigious CAP accreditation for all our Labs across India. Our business has grown two-fold in the past 3 years and now we also offer diagnostics services in South Asia, Middle East, Eastern Europe and Africa.
Our expert scientific team, data scientists and bioinformaticians fuel our genomics research and we have successfully built research pipelines addressing immuno-oncology, biomarker discovery, companion diagnostics and population-based genomic studies that taps the rich Indian diverse genotype.
We have worked extensively on building clinical databases of more than 1 million patients through collaborations. We have a repository of clinical, phenotypic and genomics data for 170,000 patients to provide insights into complex diseases at genetic and molecular level. Since the company works extensively in the Indian sub-continent, we have access to data that provides insights into genetic diversity of Indian population for more than 4,500 population groups.
Over the years we have also focussed on building tools and IP that could be leveraged by researchers and pharmaceutical companies to aid in drug discovery and clinical trial. These tools cover disease segments such as oncology, diabetes, ophthalmology, cardiology and other rare diseases.
MedGenome is a founding member of GenomeAsia 100K, an initiative to sequence 100,000 Genomes in Asia, which would enable us to provide a unique resource of genetic research for the world.
Headquartered in California, USA we have a workforce of more than 450 people across the globe with offices in Bangalore, Kochi, Mumbai, Delhi, Chennai, and Singapore.
Founder Chairman and Global CEO
Founder Chairman and Global CEO
Vice President, R & D
Vice President, Bioinformatics
Director, Corporate Planning, Marketing & Communications
Chief Operating Officer
Chief Information Officer
Chief Financial Officer
Chief Commercial Officer
Sam Santhosh founded MedGenome in 2013 as a spin off from SciGenom, which he had founded in 2009. He is a science savvy entrepreneur with close to three decades of experience in launching and running successful businesses. Passionate about science & technology, Sam firmly believes that as technology was the key driver for growth in the latter half of the 20th century, so would be genomics in the 21st century. Through MedGenome, he has transformed the medical genomics and diagnostics space in India and showed path for others to emulate. At MedGenome, he provides strategic direction, oversees business development plans and helps raise capital for future growth. He is also an investor and mentor for many other companies. Currently, he is an Advisor/Board member at Impelsys Inc, New York, ePay Healthcare, San Francisco, SciGenom Labs, Cochin, AgriGenome, Hyderabad, Emerge Ventures, Singapore and the Centre for Commercialization of Antibodies (CCAB) Toronto, Canada. Previously, he was the Founder, CEO and Managing Director of California Software Limited (Calsoft). Sam holds a degree in Engineering from University of Calicut and an MBA from IIM Calcutta. He has attended Executive education programs at MIT and Singularity University.
Mahesh Pratapneni is the cofounding investor and Board Member of MedGenome. He has led strategy, partnerships and corporate development including fundraising for the company. Mahesh is Founder and MD of Emerge Ventures that specializes in incubating product companies in the education, healthcare, and data/analytics sectors. He is known for building outstanding global teams and comes with broad experience in product visualization, development, management and building global delivery models. He holds a B. Tech. degree in Electronics and Communications from IIT Madras and an MBA from IIM Calcutta.
Dhiraj Rajaram is an entrepreneur who is passionate about technology. In his career spanning over two decades he has been named as Fortune’s 40 under 40 and awarded Entrepreneur of the Year by Ernst & Young and Economic Times. He is the founder, Chairman and CEO of Mu Sigma Inc, which has got the distinction of being one of the first Indian technology companies that is valued over 1 billion USD. At Mu Sigma, Dhiraj is responsible for vision and strategic direction, building teams, aligning organizational resources to a customer centric vision and delivering profitable growth. Prior to Mu Sigma, Dhiraj worked as a management consultant at Booz Allen Hamilton and PricewaterhouseCoopers. He holds an MBA from the University of Chicago, an M.S. in Computer Engineering from Wayne State University, and a bachelor’s degree from College of Engineering Guindy, Anna University.
Anjana Sasidharan is a Principal with Sequoia Capital India. She focuses on investments in the consumer and healthcare sectors. Prior to joining Sequoia, Anjana was associated with McKinsey & Co for four years where she advised clients across multiple sectors in India on Strategy as well as Sales & Marketing. She holds an MBA from the IIM, Ahmedabad and a BS in Electronics & Communication Engineering from NIT, Tiruchirappalli where she was a Lucent Global Science Scholar.
Dr. Stephan C Schuster is currently the Research Director and Professor at the Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technical University, Singapore. Dr .Schuster has over 15 years of experience setting up and operating centralized sequencing core labs at Max Plank Institute in Germany and Penn State in the US. He won the Science magazine’s break through of the year award in 2006 (runner up) and 2008 (Top 10). He was also awarded the Time Magazine’s top ten Scientific discoveries in 2008 and along with W. Miller was among Time magazine’s top 100 most influential people of 2009. His research interests include Metagenomics, Evolutionary Biology and ancient DNA.
Dr. I. C. Verma is currently the head of the Department of Genetic Medicine at Sri Ganga Ram Hospital, New Delhi. Previously he was a Professor of Pediatrics and Genetics in AIIMS, New Delhi. He received genetics training in the UK, USA & Switzerland. He is a Fellow of the Royal College of Physicians, London, the American Academy of Pediatrics, and the National Academy of Medical Sciences, New Delhi. He has received a number of national awards – Ranbaxy Science Award, ICMR, NAMS and BC Roy Medical Council award. He is a Member and Vice-chairman of the Ethics Committee of the International Human Genome Organization (HUGO) and serves as a genetics adviser for the WHO in Geneva, and to Roche Genetics in Basel. He has vast experience in genetic counseling, serving about 2000 cases with genetic problems every year, and bringing the benefits of genetics and genomics to large number of patients.
Dr. C. N. Ramchand serves as the Chief Executive Officer and President of Saksin Lifesciences Pvt Ltd. and MagGenome Technologies Pvt Ltd. Dr.Ramchand has 30 years of industrial and academic experience in the field of drug discovery, nanotechnology and nutraceuticals. He has held key leadership positions such as India Director at Kemin Industries, India and Vice President & Head of New Drug Discovery (biological) Research Programme at Sun Pharma Advances Research Centre (SPARC) India. He has also held the position of Joint Co-ordinator and Head, Laboratory Research Program at Biomedical Sciences, University of Sheffield and Northern General Hospital Sheffield, UK, a prestigious University Position. Prior to this he was the Sr. Scientist and Project Head at the Institute of Biological Psychiatry at University of Wales, Bangor, UK. Dr. Ramchand has published over 70 peer-reviewed papers in international journals, edited 5 books, has over 40 patents.
MedGenome Institutional Ethics Committee (MG-IEC) is an independent body constituted under the authority of the chairman with the primary goal of safeguarding the rights and wellbeing of research participants. The chairperson of MG-IEC is appointed from a different institution and the appointment of IEC members is solely based on their competence, experience and integrity.
The MG-IEC will review all types of research proposals involving human participants with a view to safeguard the dignity, rights, safety and wellbeing of all actual and potential research participants before approving the research proposals. The goals of research, however important, should never be permitted to override the health and wellbeing of the research subjects.
The MG-IEC will ascertain whether all the cardinal principles of research ethics viz., Autonomy, Beneficence, Non-maleficence, Respect for Free and Informed Consent, Respect for Human Dignity, Respect for Vulnerable Persons, Respect for Privacy and Confidentiality and Justice are taken care of in planning, conducting and reporting of the proposed research. For this purpose, it will look into the aspects of protocol review, selection of participants, voluntary participation of potential participants, informed consent process, risk benefit ratio, distribution of burden and benefit, maintenance of privacy and confidentiality and provisions for appropriate compensations. It will review the proposals before the commencement of the study as well as review periodically until the completion of the study through appropriate well-documented procedures.
|MEMBERS OF MG-IEC|
|Chairperson||Dr. Vijayalakshmi M|
|Member Secretary||Padmavathy R|
|Scientist||Dr. Lakshmi Mahadevan|
|Basic Medical Scientist||Dr. Kumaramanickavel G|
|Scientist||Dr Ramchand CN|
|Legal Expert/Lawyer||Srijith PR|
|Philosopher||Dr. Rajamohan EK|
|Basic Medical Scientist||Dr. Álex Baby Paul|
|Lay Person||Babu AG|
|Social Scientist / Social Worker||Vinita Vijayakumar|
Phone Number : 9496665432 / 9940678632